Results 1 to 10 of about 9,329 (213)

Flucytosine and its clinical usage

Therapeutic Advances in Infectious Disease, 2023
Flucytosine is an antifungal agent first licensed in the 1970’s. However, its clinical value has long been overlooked and its availability across the globe is limited.
L S M Sigera, David W Denning
exaly   +3 more sources

New Mechanisms of Flucytosine Resistance in C. glabrata Unveiled by a Chemogenomics Analysis in S. cerevisiae. [PDF]

PLoS ONE, 2015
5-Flucytosine is currently used as an antifungal drug in combination therapy, but fungal pathogens are rapidly able to develop resistance against this drug, compromising its therapeutic action. The understanding of the underlying resistance mechanisms is
Catarina Costa, Andreia Ponte, Pedro Pais, Rui Santos, Mafalda Cavalheiro, Takashi Yaguchi, Hiroji Chibana, Miguel Cacho Teixeira   +7 more
doaj   +2 more sources

Time to embrace access programmes for medicines: lessons from the South African flucytosine access programme [PDF]

International Journal of Infectious Diseases, 2020
Background: Cryptococcal meningitis (CM) is estimated to cause 181 000 deaths annually, with the majority occurring in Sub-Saharan Africa. Flucytosine is recommended by the World Health Organization as part of the treatment for CM.
Amir Shroufi, Nelesh P. Govender, Graeme Meintjes, John Black, Jeremy Nel, Mahomed-Yunus S. Moosa, Colin Menezes, Halima Dawood, Douglas Wilson, Laura Trivino Duran, Olawale Ajose, Richard A. Murphy, Thomas Harrison, Angela Loyse, Carol Ruffell, Gilles Van Cutsem   +15 more
doaj   +2 more sources

Flucytosine Pharmacokinetics in a Critically Ill Patient Receiving Continuous Renal Replacement Therapy [PDF]

Case Reports in Critical Care, 2015
Purpose. A case report evaluating flucytosine dosing in a critically ill patient receiving continuous renal replacement therapy. Summary. This case report outlines an 81-year-old male who was receiving continuous venovenous hemofiltration (CVVH) for ...
Megan E. Kunka, Elizabeth A. Cady, Heejung C. Woo, Melissa L. Thompson Bastin   +3 more
doaj   +2 more sources

Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa [PDF]

BMC Health Services Research, 2021
Background Cryptococcal meningitis in HIV-infected patients in sub-Saharan Africa accounts for three-quarters of the global cases and 135,000 deaths per annum. Current treatment includes the use of fluconazole and amphotericin B.
Jacqui Miot, Trudy Leong, Simbarashe Takuva, Andrew Parrish, Halima Dawood   +4 more
doaj   +2 more sources

Fluconazole plus flucytosine versus fluconazole alone for adults with HIV-associated cryptococcal antigenaemia identified through screening: a multi-centre phase III randomised-controlled trial [PDF]

Trials
Background Despite the expansion of antiretroviral treatment programmes, the incidence and mortality of HIV-associated cryptococcal meningitis remain high in Africa. Cryptococcal antigen (CrAg) in the blood precedes meningitis.
Kyla Murphy, Jeremy S. Nel, Mahomed-Yunus Moosa, Douglas P. Wilson, Merika Tsitsi, Sayoki Mfinanga, Sokoine Kivuyo, Denise Kyazze, Nowshad Alam, Graeme Meintjes, Michelle Eriksson, Jack Adams, Colin Menezes, Ebrahim Variava, John Black, Marise Bremer, Vu Quoc Dat, Thuy Le, Charlotte Schutz, Angela Loyse, Rachel M. Wake, David S. Lawrence, Duolao Wang, Shabbar Jaffar, Joseph N. Jarvis, Thomas S. Harrison, Síle F. Molloy, Nelesh P. Govender   +27 more
doaj   +2 more sources

Antifungal Susceptibility of Clinical Meyerozyma guillermondii Isolates Obtained Between 1994 and 2014: Original Research and Comparison with Published Data [PDF]

Pathogens
(1) Background: Meyerozyma guilliermondii is a yeast species widely distributed in the natural environment and one of the rare emerging pathogens capable of causing difficult to treat, severe infections.
Aleksandra Górzyńska, Daria Konarska, Agnieszka Korzeniowska-Kowal, Anna Wzorek, Bartosz Pencakowski, Urszula Nawrot   +5 more
doaj   +2 more sources

Clonal Population of Flucytosine-Resistant Candida tropicalis from Blood Cultures, Paris, France

Emerging Infectious Diseases, 2008
Candida tropicalis is a diploid ascomycetes yeast responsible for 4%–24% of candidemia. Resistance to flucytosine is rarely described for this species but was observed for 45 (35%) of 130 C.
Marie Desnos-Ollivier, Stéphane Bretagne, Claire Bernède, Vincent Robert, Dorothée Raoux, Elisabeth Chachaty, Elisabeth Forget, Claire Lacroix, Françoise Dromer   +8 more
doaj   +2 more sources

Impact of Biofilm Formation by Vaginal Candida albicans and Candida glabrata Isolates and Their Antifungal Resistance: A Comprehensive Study in Ecuadorian Women [PDF]

Journal of Fungi
Candida albicans and Candida glabrata are key fungal pathogens linked to candidiasis, with rising concerns due to antifungal resistance and biofilm abilities. However, data from Latin America remains limited.
Ariana Cecibel Cedeño-Pinargote, Nicolás Renato Jara-Medina, Carlos C. Pineda-Cabrera, Darío F. Cueva, María P. Erazo-Garcia, Eduardo Tejera, António Machado   +6 more
doaj   +2 more sources

Successful use of isavuconazole as secondary prophylaxis of cryptococcal meningitis in a person living with HIV and AIDS: a case report [PDF]

Therapeutic Advances in Infectious Disease
Cryptococcal meningitis (CM) is a severe opportunistic infection in people living with HIV (PLWH). We report a 54-year-old man with advanced HIV infection who presented with CM due to Cryptococcus neoformans .
Carmela Pinnetti, Alessandro Giacinta, Federico Cecilia, Francesco Baldini, Annalisa Mondi, Saba Gebremeskel Teklè, Susanna Grisetti, Marta Camici, Donatella Vincenti, Stefania Carrara, Carla Fontana, Andrea Antinori   +11 more
doaj   +2 more sources